2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). (September 2015) - Oza, A.M.; Selle, F.; Davidenko, I.; Korach, J.; Mendiola, C.; Gocze, P.; Pautier, P.; Chmielowska, E.; Bamias, A.; DeCensi, A.; Zvirbule, Z.; Gonzalez-Martin, A.; et al.